Genzyme and Relational Investors: Science and Business Collide? Custom Case Solution & Analysis

1. Evidence Brief (Case Researcher)

Financial Metrics

Genzyme 2009 Revenue: $4.5B.
Genzyme 2009 R&D spend: $1.1B (~24% of revenue).
Relational Investors (RI) stake: 1.5% of Genzyme (valued at ~$400M).
Genzyme stock performance: Underperformed the S&P 500 and Biotech Index over the prior 3-year period.
Manufacturing disruption impact: 2009 Allston plant contamination led to supply shortages of Cerezyme and Fabrazyme, costing an estimated $1B in lost revenue.

Operational Facts

Product Concentration: Cerezyme and Fabrazyme represented a significant portion of revenue and were produced at the troubled Allston facility.
Governance: CEO Henri Termeer had led the firm since 1983. Board characterized by long-tenured members with limited independent oversight.
Strategy: High-risk, high-reward approach to rare disease (orphan drug) R&D.

Stakeholder Positions

Relational Investors (Ralph Whitworth): Argues for operational efficiency, board refreshment, and a focus on core profitability over R&D sprawl.
Henri Termeer: Defends the long-term vision of rare disease innovation; views activist intervention as a threat to the scientific mission.

Information Gaps

Specific breakdown of R&D return on invested capital (ROIC) by program.
Detailed internal audit of the Allston plant remediation timeline beyond public statements.

2. Strategic Analysis (Strategic Analyst)

Core Strategic Question

How should Genzyme balance its commitment to high-risk orphan drug innovation against the immediate need to restore operational stability and shareholder confidence following the Allston plant crisis?

Structural Analysis

Value Chain: The manufacturing failure at Allston created a single point of failure in the distribution chain, destroying the company competitive advantage in supply reliability.
Agency Theory: Termeer long tenure created an entrenchment risk, where the board prioritized the status quo over necessary operational discipline.

Strategic Options

Option 1: Aggressive Restructuring. Divest non-core assets, slash R&D by 20%, and install a new board. Trade-off: Restores margins but risks destroying the core scientific pipeline.
Option 2: Operational Stabilization & Governance Reform. Retain core R&D, appoint independent board members, and tie executive compensation to manufacturing uptime. Trade-off: Slower financial recovery but preserves long-term capability.
Option 3: Strategic Sale. Seek a buyer for the entire company. Trade-off: Provides immediate exit for shareholders but likely undervalues the long-term potential of the orphan drug pipeline.

Preliminary Recommendation

Pursue Option 2. Genzyme is fundamentally a science-led firm; drastic R&D cuts would cause irreparable damage. Governance reform is the necessary catalyst to ensure operational discipline is treated with the same rigor as scientific discovery.

3. Implementation Roadmap (Implementation Specialist)

Critical Path

Months 1-3: Appoint three new independent board members with expertise in manufacturing and supply chain management.
Months 3-6: Complete Allston plant remediation and secure FDA sign-off.
Months 6-12: Implement a new performance-based compensation structure for the leadership team tied to manufacturing output and product availability.

Key Constraints

Regulatory Compliance: The FDA holds the ultimate timeline for production resumption.
Cultural Inertia: The scientific staff may resist the shift toward manufacturing efficiency as a core performance metric.

Risk-Adjusted Implementation

Contingency: If the FDA delays Allston approval beyond month 6, the company must prepare a secondary manufacturing contingency plan (outsourcing or capacity expansion at other sites) to prevent further market share erosion.

4. Executive Review and BLUF (Executive Critic)

BLUF

Genzyme is a classic case of scientific hubris masking operational decay. The manufacturing failure at Allston is not a technical issue; it is a symptom of a board that failed to hold management accountable for basic operational hygiene. The firm must pivot from a founder-centric R&D culture to a disciplined, execution-oriented model. Appointing independent directors with industrial, rather than biotech, backgrounds is not optional. The company must prove it can manufacture its existing products consistently before it can justify the continued high-burn rate of its R&D pipeline. If management resists these changes, the board must initiate a leadership transition.

Dangerous Assumption

The assumption that Genzyme can recover its market position through R&D alone. The brand and competitive moat are currently being eroded by supply unreliability.

Unaddressed Risks

Talent Flight: Aggressive management changes may trigger an exodus of key scientists.
Market Share Erosion: Competitors are filling the void left by Cerezyme shortages; regaining that share is significantly harder than holding it.

Unconsidered Alternative

Splitting the company into two entities: a mature commercial business (focused on established orphan drugs) and a spin-off R&D entity. This would allow the commercial side to focus on operational excellence while the R&D side attracts capital from investors with higher risk tolerance.

Verdict: APPROVED FOR LEADERSHIP REVIEW